159.77

2.86% -4.71

After Hours: 159.77

Insulet Corp (PODD)

Overview News Price History Option Chain Financials Why PODD Down? Discussions Forecast

Insulet Corp stock is traded at $159.77, with a volume of 1.37M. It is down -2.86% in the last 24 hours and up +4.27% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Previous Close:

$164.48

Open:

$163.7

24h Volume:

1.37M

Relative Volume:

0.95

Market Cap:

$11.07B

Revenue:

$2.90B

Net Income/Loss:

$302.80M

P/E Ratio:

37.19

EPS:

4.2965

Net Cash Flow:

$387.80M

1W Performance:

+1.29%

1M Performance:

+4.27%

6M Performance:

-45.72%

1Y Performance:

-46.93%

1-Day Range:

$153.64

$164.40

1-Week Range:

$152.16

$167.82

52-Week Range:

$138.79

$354.88

Insulet Corp Stock (PODD) Company Profile

Name

Insulet Corp

Sector

Healthcare (1100)

Industry

Medical Devices (142)

Phone

978-600-7000

Address

100 NAGOG PARK, ACTON, MA

Employee

5,400

Twitter

@insulet_uk

Next Earnings Date

2026-08-06

Latest SEC Filings

PODD's Discussions on Twitter

Compare PODD vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PODD Insulet Corp	159.77	10.55B	2.90B	302.80M	387.80M	4.2965
ABT Abbott Laboratories	95.63	158.05B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	324.73	120.70B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.06	100.14B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.60	63.44B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	95.18	52.09B	6.30B	1.07B	1.09B	1.8406

Insulet Corp Stock (PODD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Downgrade	Rothschild & Co Redburn	Buy → Neutral
Apr-07-26	Downgrade	Citigroup	Buy → Neutral
Jan-27-26	Resumed	TD Cowen	Hold
Jan-12-26	Downgrade	Barclays	Overweight → Equal Weight
Dec-16-25	Initiated	Evercore ISI	Outperform
Nov-19-25	Upgrade	UBS	Neutral → Buy
Oct-21-25	Resumed	Stifel	Buy
Sep-08-25	Resumed	Oppenheimer	Outperform
Jun-16-25	Initiated	Truist	Buy
May-30-25	Initiated	Goldman	Buy
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform
Nov-06-24	Initiated	Bernstein	Outperform
May-30-24	Initiated	Redburn Atlantic	Buy
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-02-23	Upgrade	Jefferies	Hold → Buy
Aug-21-23	Upgrade	Citigroup	Neutral → Buy
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-12-22	Initiated	Jefferies	Hold
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Buy
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy
Feb-02-22	Upgrade	UBS	Neutral → Buy
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-21-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Overweight
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-19-21	Upgrade	Canaccord Genuity	Hold → Buy
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Jul-28-20	Initiated	Wells Fargo	Overweight
Apr-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-03-20	Initiated	BofA/Merrill	Neutral
Mar-31-20	Downgrade	Berenberg	Buy → Hold
Mar-05-20	Initiated	Citigroup	Buy
Dec-10-19	Initiated	CFRA	Sell
Oct-23-19	Initiated	Stifel	Hold
Oct-18-19	Downgrade	Canaccord Genuity	Buy → Hold
Oct-14-19	Downgrade	BTIG Research	Buy → Neutral
Oct-04-19	Downgrade	UBS	Buy → Neutral
Oct-03-19	Downgrade	Guggenheim	Buy → Neutral
Aug-06-19	Upgrade	JP Morgan	Neutral → Overweight
Jun-10-19	Downgrade	Northland Capital	Outperform → Market Perform
May-06-19	Upgrade	BTIG Research	Neutral → Buy
Apr-20-18	Initiated	Berenberg	Buy
Feb-22-18	Reiterated	Barclays	Overweight
Jan-08-18	Upgrade	Raymond James	Mkt Perform → Outperform
Nov-03-17	Upgrade	Canaccord Genuity	Hold → Buy
Sep-15-17	Initiated	Barclays	Overweight

View All

Insulet Corp Stock (PODD) Latest News

Jul 01, 2026

Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch

Jul 01, 2026

Insulet will report Q2 results Aug. 5, with a call at 8 a.m. - Stock Titan

Jul 01, 2026

Insulet Corp (NASDAQ:PODD): Strong Growth Stock Consolidating Near Resistance for a Potential Breakout - ChartMill

Jul 01, 2026

Jun 30, 2026

A Look at Insulet Corp (PODD) After 3.5% Decline -- GF Value $39 - GuruFocus

Jun 30, 2026

PODDInsulet Corp Latest SEC Filings - Finviz

Jun 30, 2026

Insulet Corporation's Stock Price Suffers a Dip to $152.25, Recording a 3.48% Drop: Market Analysis and Insights - Smartkarma

Jun 30, 2026

Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Jun 30, 2026

Patient Monitoring Stocks Q1 Earnings Review: Insulet (NASDAQ:PODD) Shines - Yahoo Finance

Jun 30, 2026

Could Insulet’s (PODD) Russell 2500 Debut Quietly Reframe the Omnipod Investment Narrative? - Yahoo Finance

Jun 30, 2026

Insulet builds on Omnipod 5 momentum. Earnings beat keeps growth story intact - AD HOC NEWS

Jun 30, 2026

Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet - Investing.com

Jun 28, 2026

Omnipod DASH from Insulet Corp.tubeless insulin that fits daily life - Ad-hoc-news.de

Jun 28, 2026

Jun 26, 2026

Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN

Jun 26, 2026

Insulet Analyst Ratings and Price Targets | NASDAQ:PODD - Benzinga

Jun 26, 2026

Insulet Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 26, 2026

T. Rowe Price Mid-Cap Growth Portfolio's Insulet Corp(PODD) Holding History - GuruFocus

Jun 26, 2026

If You Invested $1000 in Insulet 10 Years Ago, This Is How Much You'd Have Now - Yahoo! Finance Canada

Jun 26, 2026